DeepScan Diagnostics Company Profile

Background

DeepScan Diagnostics is a Finnish company founded in 2022, dedicated to transforming veterinary diagnostics through early disease detection in dogs. The company's mission is to empower veterinarians and pet owners by providing predictive diagnostics that can identify health issues before clinical symptoms appear, thereby enhancing the quality and longevity of canine lives. DeepScan specializes in developing non-invasive liquid biopsy tests that detect cancer markers in blood samples, positioning itself as a pioneer in preventive pet healthcare.

Key Strategic Focus

DeepScan's strategic focus centers on:

• Early Detection of Canine Diseases: Developing advanced diagnostic tools to identify diseases such as cancer at their earliest stages, enabling timely and effective interventions.

• Non-Invasive Testing: Utilizing liquid biopsy techniques to analyze cell-free DNA (cfDNA) in blood samples, offering a less invasive alternative to traditional tissue biopsies.

• Integration with Veterinary Practices: Collaborating with veterinary clinics to incorporate cfDNA testing into routine health check-ups, thereby enhancing standard diagnostic panels.

• Global Expansion: Establishing partnerships to distribute their diagnostic tests internationally, with a notable collaboration in the United States.

Financials and Funding

DeepScan Diagnostics has attracted investment from Calm/Storm Ventures, a venture capital firm that supports innovative startups. The funding is intended to support the development and commercialization of DeepScan's diagnostic tests, as well as to facilitate international expansion efforts.

Pipeline Development

DeepScan is in the advanced stages of developing a liquid biopsy test for early cancer detection in dogs. The test is designed to:

• Detect Cancer Markers: Identify cfDNA released by cancerous cells, allowing for early diagnosis before clinical symptoms manifest.

• Monitor Treatment Efficacy: Measure cfDNA levels over time to assess the effectiveness of treatments for chronic inflammation and cancer.

The company launched its first product in late 2024 and is actively seeking partners and team members to further its mission.

Technological Platform and Innovation

DeepScan's innovation is rooted in its proprietary cfDNA analysis platform, which offers:

• Advanced cfDNA Measurement: Utilizing state-of-the-art PCR and sequencing technologies to detect and quantify cfDNA with high accuracy.

• Non-Invasive Diagnostics: Providing a simple blood test that can be integrated into routine veterinary care, reducing the need for invasive procedures.

• Early Disease Detection: Enabling the identification of diseases such as cancer, organ damage, and chronic conditions before they become clinically apparent.

Leadership Team

DeepScan's leadership comprises experienced professionals with diverse backgrounds:

• William von der Pahlen: Co-founder & CEO, leading the company's strategic vision and operations.

• Antti Pasila: Co-founder & Chief Business Development Officer, focusing on business growth and partnerships.

• Katja Kivinen, PhD: Chief Scientific Officer, overseeing research and development initiatives.

• Franz Mittler: Chief Commercial Officer, managing commercial strategies and market expansion.

• Anssi Rantanen: Chief Growth Officer, driving the company's growth strategies.

• Milja Tikkanen: Head of Laboratory, ensuring the quality and accuracy of laboratory operations.

• Emmi Hurskainen: Laboratory Manager, supporting laboratory processes and management.

• Gugan Eswaran, PhD: Head of Research and Development, leading the development of new diagnostic technologies.

• Petra Jaakonsaari: Research Coordinator, facilitating research projects and collaborations.

• Juha Kere: Founding Scientific Advisor, providing scientific guidance and expertise.

• Hannes Lohi: Founding Advisor, offering strategic advice and support.

Leadership Changes

As of July 2025, there have been no significant changes or appointments within DeepScan's leadership team.

Competitor Profile

Market Insights and Dynamics

The veterinary diagnostics market is experiencing significant growth, driven by increasing pet ownership and a heightened focus on pet health. The demand for early disease detection and non-invasive diagnostic methods is rising, positioning companies like DeepScan at the forefront of this evolving industry.

Competitor Analysis

Key competitors in the veterinary diagnostics space include:

• Antech Diagnostics: Offers a comprehensive range of diagnostic tests and services for veterinary practices.

• IDEXX Laboratories: Provides a wide array of veterinary diagnostic products and services, including laboratory tests and imaging solutions.

• Zoetis: Develops and markets veterinary vaccines and medicines, along with diagnostic products.

These companies focus on various aspects of veterinary diagnostics, from laboratory services to point-of-care testing, contributing to a competitive landscape that emphasizes innovation and comprehensive care solutions.

Strategic Collaborations and Partnerships

DeepScan has established significant partnerships to enhance its market presence:

• Sploot Veterinary Care: In June 2025, DeepScan entered into an exclusive regional U.S. partnership with Sploot Veterinary Care to introduce its cfDNA screening tests to the U.S. market.

• Breed Associations: Collaborated with breed associations, such as the Finnish Dobermann Association, to collect blood samples for research and product development.

Operational Insights

DeepScan's strategic considerations include:

• Market Positioning: Differentiating itself through the development of non-invasive, early detection tests that can be seamlessly integrated into routine veterinary care.

• Competitive Advantages: Leveraging proprietary cfDNA technology to offer accurate and early diagnostics, setting a new standard in veterinary diagnostics.

• Regulatory Compliance: Ensuring adherence to veterinary regulatory standards to facilitate market entry and acceptance.

Strategic Opportunities and Future Directions

DeepScan's future directions encompass:

• Product Portfolio Expansion: Developing additional diagnostic tests for a broader range of canine diseases and conditions.

• Technological Advancements: Enhancing the cfDNA analysis platform to improve accuracy and expand diagnostic capabilities.

• Global Market Penetration: Establishing partnerships and distribution channels to introduce products to international markets.

• Research and Development: Investing in ongoing research to stay at the forefront of veterinary diagnostics innovation.

Contact Information

For more information, visit DeepScan Diagnostics' official website.